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Complement C1q is a soluble pattern recognition molecule comprising six heterotrimeric 
subunits assembled from three polypeptide chains (A–C). Each heterotrimer forms a 
collagen-like stem prolonged by a globular recognition domain. These recognition 
domains sense a wide variety of ligands, including pathogens and altered-self compo-
nents. Ligand recognition is either direct or mediated by immunoglobulins or pentraxins. 
Multivalent binding of C1q to its targets triggers immune effector mechanisms mediated 
via its collagen-like stems. The induced immune response includes activation of the 
classical complement pathway and enhancement of the phagocytosis of the recognized 
target. We report here, the first production of a single-chain recombinant form of human 
C1q globular region (C1q-scGR). The three monomers have been linked in tandem 
to generate a single continuous polypeptide, based on a strategy previously used for 
adiponectin, a protein structurally related to C1q. The resulting C1q-scGR protein was 
produced at high yield in stably transfected 293-F mammalian cells. Recombinant C1q-
scGR was correctly folded, as demonstrated by its X-ray crystal structure solved at 
a resolution of 1.35  Å. Its interaction properties were assessed by surface plasmon 
resonance analysis using the following physiological C1q ligands: the receptor for C1q 
globular heads, the long pentraxin PTX3, calreticulin, and heparin. The 3D structure and 
the binding properties of C1q-scGR were similar to those of the three-chain fragment 
generated by collagenase digestion of serum-derived C1q. Comparison of the inter-
action properties of the fragments with those of native C1q provided insights into the 
avidity component associated with the hexameric assembly of C1q. The interest of this 
functional recombinant form of the recognition domains of C1q in basic research and its 
potential biomedical applications are discussed.
Keywords: innate immune recognition, complement, c1q, protein engineering, X-ray crystallography, surface 
plasmon resonance
Abbreviations: C1q-GR, globular region of C1q; C1q-scGR, single-chain globular region of C1q; CRT, calreticulin; gC1qR, 
receptor for the globular head of C1q; SPR, surface plasmon resonance.
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inTrODUcTiOn
The soluble defense collagens are oligomeric innate immune 
pattern recognition receptors (PRRs), which are composed of 
N-terminal collagen-like stems prolonged by C-terminal globu-
lar trimeric pattern recognition domains [reviewed in Ref. (1)]. 
According to the nature of their recognition domain, these PRRs 
can be divided into three families in human, namely, proteins 
with gC1q domains (C1q and adiponectin), C-type lectin carbo-
hydrate recognition domains (lung surfactant proteins A and D, 
mannan-binding lectin (MBL), collectins kidney 1 and liver 1), 
and fibrinogen-like domains (ficolins). Following target recogni-
tion, C1q and collectins (except surfactant proteins) or ficolins 
have the capacity to trigger activation of the classical and lectin 
pathways of complement for microbial killing and phagocytosis, 
through proteases associated with their collagen stems.
The C1q molecule is a complex defense collagen, being 
assembled from six heterotrimeric subunits, each consisting 
of three homologous, yet distinct polypeptide chains (A–C) 
encoded by the C1QA, C1QB, and C1QC genes oriented in the 
A–C–B order on human chromosome 1p (2). C1q also features 
the most versatile recognition properties, being able to identify 
not only bacterial and viral pathogens, either directly or through 
other immune proteins such as antibodies and pentraxins, but 
also many altered self elements, including β-amyloid fibrils (3), 
the pathological form of the prion protein (4, 5), modified low-
density lipoproteins (6), and apoptotic cells (7–9).
Production of the C1q globular region (C1q-GR) by limited 
proteolysis of the serum-derived protein with collagenase allowed 
resolution of its X-ray crystal structure. The resulting compact 
heterotrimeric structure revealed differences in the surface 
charges of the subunits, a key factor for the versatility of C1q 
binding properties (10, 11). A further step toward understanding 
C1q binding properties was accomplished with the production 
of recombinant forms of the individual gC1q domains fused to 
maltose-binding protein, which revealed that these domains 
are functionally autonomous modules with differential ligand- 
binding properties (12). Site-directed mutagenesis studies pro-
vided information about the residues involved in the interaction 
of C1q with some of its ligands (13–16). However, elucidation of 
the C1q recognition properties in the more physiological context 
of the heterotrimeric globular regions still awaits the availability 
of the corresponding recombinant fragment.
We report here, the production of a single-chain recombinant 
form of human C1q globular region (C1q-scGR). The three 
monomers have been linked in tandem to generate a single 
continuous polypeptide, based on a strategy previously used 
to generate a single-chain form of the homotrimeric globular 
domain of adiponectin, a protein structurally related to C1q 
(17). The C1q-scGR recombinant protein was produced at high 
yield in stably transfected mammalian cells. Its physicochemi-
cal, structural, and functional analysis shows that it is correctly 
folded and retains the ability to associate with physiological C1q 
ligands, including the long pentraxin PTX3, the receptor for the 
globular heads of C1q (gC1qR), calreticulin (CRT), and heparin. 
The interest of this fragment in basic research and its potential 
biomedical applications will be discussed.
MaTerials anD MeThODs
Proteins and reagents
C1q was purified from human serum and quantified, as described 
previously (18). The globular regions of C1q were prepared by 
collagenase digestion of C1q, as described previously (3), and 
their molar concentration estimated using a Mw value of 48,000 
and an absorption coefficient (A1%, 1  cm) at 280  nm of 0.93. 
Recombinant human PTX3, gC1qR, and CRT were produced, as 
described previously (19–21). Streptavidin and heparin-biotin 
sodium salt (Mw 15  kDa) were procured from Sigma-Aldrich. 
Oligonucleotides were purchased from Eurogentec. Restriction 
and modification enzymes were from New England Biolabs.
cloning of the single-chain globular 
Domain of human c1q
For recombinant protein expression in the baculovirus/insect 
cells system, a synthetic cDNA encoding residues 85–223 of 
mature C1qA, a Gly–Ser–Gly linker, residues 87–217 of mature 
C1qC (gC1qC), a Gly–Ser–Ala linker, and residues 90–226 of 
mature C1qB (gC1qB), cloned in frame with the melittin signal 
peptide of the pNT-Bac vector (22) (pNT-Bac–C1q-scGR), was 
purchased from GeneCust.
For expression in mammalian 293-F cells, an intermediate 
construct was generated from the pcDNA3.1–C1qA vector (23) 
by removing residues 1–87 of mature C1qA by site-directed 
mutagenesis, allowing in frame cloning of residues 88–223 
of C1qA with the native signal peptide of C1qA (pcDNA3.1–
gC1qA). A DNA fragment encoding the Gly–Ser–Gly linker, 
gC1qC, the Gly–Ser–Ala linker, and gC1qB was amplified using 
VentR polymerase and pNT-Bac–C1q-scGR as a template and 
inserted into pcDNA3.1–gC1qA by site-directed mutagenesis. 
The resulting construct (called pcDNA3.1–C1q-scGR) was char-
acterized by restriction mapping and checked by double-stranded 
DNA sequencing (GATC Biotech).
Production of c1q-scgr in eukaryotic 
cells and Protein Purification
Generation of a recombinant baculovirus from the pNT-Bac–
C1q-scGR plasmid using the Bac-to-Bac system (Invitrogen) and 
infection of Trichoplusia ni (High Five) insect cells was performed, 
as described previously (24). Stably transfected cells producing 
C1q-scGR were obtained by transfection of FreeStyle 293-F cells 
with the pcDNA3.1–C1q-scGR plasmid using 293-fectin and 
subsequent selection with 400  μg/ml G418 as recommended 
by the manufacturer (Invitrogen). The cells were expanded in 
the Freestyle expression medium (Invitrogen) and the culture 
supernatant harvested and replaced every 72 h up to three times.
The insect and mammalian cell culture supernatants contain-
ing C1q-scGR (500 ml) were dialyzed against 50 mM MES, 25 mM 
NaCl, pH 6.4, and loaded at 1.5 ml/min onto a SP Sepharose Fast 
Flow column (GE Healthcare) (50 ml) equilibrated in the same 
buffer. Elution was carried out by applying a 1-l linear gradient 
from 25 to 500 mM NaCl in the same buffer. The fractions con-
taining the recombinant protein were identified by SDS-PAGE 
analysis, pooled, dialyzed against 50  mM Tris–HCl, 150  mM 
TaBle 1 | Data collection and refinement statistics for c1q-scgr.
reservoir solution
PDB iD
Without calcium
5hZF
With calcium
5hKJ
Data collection statistics
Unit cell lengths (Å) 81.0, 52.9, 89.9 81.1, 52.7, 89.9
Unit cell angles (°) 90, 115.2, 90 90, 115.2, 90
Resolution (Å)a 100.0–1.55 
(1.61–1.55)
100.0–1.35 
(1.4–1.35)
Rsyma 5.6 (75.3) 7.0 (67.1)
% completenessa 98.4 (96.7) 98.7 (94.7)
I/sigma (I) averagea 14.8 (1.9) 11.3 (1.8)
No. of observed reflectionsa 243,827 (25,061) 363,221 (31,079)
No. of unique reflectionsa 49,348 (5211) 74,618 (7346)
CC ½a 99.9 (56) 99.8 (68.2)
Mean Wilson B 27 21
Model refinement statistics
Rwork 0.169 0.175
Rfree 0.185 0.2021
Root mean square deviation 
bonds (Å)
0.011 0.016
Root mean square deviation 
angles (°)
1.19 1.64
aStatistics for the high-resolution bin are in parentheses.
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NaCl, pH 7.4, and concentrated to 1–5 mg/ml by ultrafiltration 
on a PM-10 membrane (Amicon). The molar concentration of 
C1q-scGR was estimated using an absorption coefficient (A1%, 
1 cm) at 280 nm of 0.93 and a Mr value of 47,534, as determined 
by mass spectrometry.
sDs-Page, n-Terminal sequence, and 
liquid chromatography–electrospray 
ionization–Time-of-Flight Mass 
spectrometry analyses
Recombinant C1q-scGR was analyzed by SDS-PAGE under non-
reducing or reducing conditions using Tris–HCl gels containing 
10% polyacrylamide. N-terminal sequence determination was 
performed using an Applied Biosystems gas-phase sequencer 
model 492 coupled online with an Applied Biosystems Model 
140C HPLC system. Liquid chromatography–electrospray 
ionization–time-of-flight (LC–ESI–TOF) mass spectrometry 
analyses of purified C1q-scGR, before and after treatment with 
Clostridium perfringens type X neuraminidase (Sigma) (0.3  U/
mg) for 5  h at 25°C, were performed using a 6210 LC–TOF 
mass spectrometer interfaced with LC pump system (Agilent 
Technologies). Samples were desalted on-line on a protein trap 
(Zorbax 300SB-C8, 5 μm, 5 mm × 0.3 mm, Agilent Technologies) 
before analysis.
analytical Ultracentrifugation
Sedimentation velocity analysis was performed using a Beckman 
XL-I analytical ultracentrifuge and an AN-50 TI rotor (Beckman 
Coulter, Palo Alto, CA, USA). Three C1q-scGR samples at 0.9, 
2.5, and 5 mg/ml were loaded into 12, 3, and 1.5 mm pathlength 
double-sector cells and centrifuged at 42,000  rpm at 6°C in 
50 mM Tris–HCl, 150 mM NaCl, and pH 7.4. Data acquisition 
was done in absorbance (at 280  nm) and interference modes. 
The sedimentation coefficients were obtained by fitting the sedi-
mentation velocity profiles to the non-interacting species model 
using the SEDFIT program,1 and the continuous distribution of 
sedimentation coefficients was obtained considering globular 
proteins. Solvent density was calculated at 1.00739 g/ml, and the 
partial specific volume was estimated at 0.724  ml/g, using the 
SEDNTERP program.2
crystallization, Data collection, and 
structure Determination
Single-chain recombinant form of human C1q globular region 
was concentrated to 5 mg/ml, and standard crystallization kits 
were screened through the EMBL HTX Lab platform at 20°C. 
Several initial hits were reproduced manually, using the hang-
ing drop method by mixing equal volumes (2 μl) of the protein 
and reservoir solutions and adding calcium in some reservoir 
solutions. The crystallization conditions used and the resulting 
crystal morphology were very similar to those obtained previ-
ously for plasma-derived C1q-GR (10). To obtain the crystal 
1 https://sedfitsedphat.nibib.nih.gov/software
2 www.bbri.org/RASMB/rasmb.html
structures presented here, the following reservoir solutions were 
used: (1) 30% PEG 8000, 0.1M Hepes, pH 7.5; (2) 23% PEG 3350, 
0.1M Tris, 0.2M NaCl, 50 mM CaCl2, pH 8.5. Diffraction data 
were recorded up to 1.35 or 1.55 Å resolution at the European 
Synchrotron Radiation facility (ESRF) beamline ID23-eh1 and 
auto-processed in the C2 space group (25). The data collection 
statistics are provided in Table 1.
The position and orientation of the C1q-scGR trimeric globu-
lar domain in the asymmetric unit were determined with the 
molecular replacement software Phaser (26). Alternative cycles of 
refinement and graphics edition were performed using Refmac5 
(27) and Coot (28), respectively. The final refinement cycles were 
performed using Phenix (29). Refinement statistics are provided 
in Table 1. Illustrations were prepared using Pymol (30).
surface Plasmon resonance studies
Analyses were performed at 25°C using a Biacore 3000 instru-
ment (GE Healthcare).
SPR Analyses on Immobilized C1q Protein Ligands
Calreticulin, gC1qR, and PTX3 were diluted to 20, 68, and 
100 μg/ml in 10 mM sodium acetate pH 4.0, 4.0, and 3.5, respec-
tively, and immobilized on a CM5 sensor chip (GE Healthcare) 
using the amine coupling chemistry in 10 mM Hepes, 150 mM 
NaCl, 3 mM EDTA, 0.005% surfactant P20, pH 7.4. The reference 
surface was submitted to the coupling steps without immobilized 
protein. Binding of C1q-scGR, C1q-GR, and C1q to immobilized 
CRT (3000–4700 RU), gC1qR (500–3400 RU), and PTX3 (5300–
6200 RU) was measured at a flow rate of 20 μl/min in 50 mM 
Tris–HCl, 150 mM NaCl, 2 mM CaCl2, 0.005% surfactant P20, 
pH 7.4. The specific binding signal was obtained by subtracting 
the background signal over the reference surface. Regeneration of 
the surfaces was achieved by 10 μl injections of 10–20 mM NaOH.
FigUre 1 | Biochemical characterization of purified c1q-scgr. (a) 
Schematic representation of mature recombinant C1q-scGR protein. (B) 
SDS-PAGE analysis of C1q-scGR, unreduced (lane 1) and reduced (lane 2). 
The molecular masses of unreduced and reduced markers (expressed in 
kilodaltons) are shown on the left and right sides of the gel, respectively. (c) 
Sedimentation velocity analysis of C1q-scGR. Analysis was performed as 
described in Section “Materials and Methods” and the continuous distribution 
of sedimentation coefficients is shown. Orange, purple and blue traces 
correspond to C1q-scGR samples at 0.9, 2.5, and 5 mg/ml, respectively 
(data acquisition in absorbance mode).
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SPR Analyses on Immobilized Heparin
Streptavidin (approximately 4000 RU) was immobilized on two 
flow cells of a CM5 sensor chip, as described previously (31). 
Biotinylated heparin was captured on the streptavidin surface 
in 10  mM Hepes, 150  mM NaCl, 0.005% surfactant P20, pH 
7.4 (HBS-P) until a coupling level of 250–300 RU was obtained. 
Serum C1q-GR and recombinant C1q-scGR were injected over 
the heparin-bound surface at 20 μl/min in HBS-P. Surfaces were 
regenerated with 10  μl of 1M NaCl. The streptavidin surface 
without bound heparin was used as a reference.
SPR Data Evaluation
Data were analyzed by global fitting either to a 1:1 Langmuir 
binding model or to a two-state reaction binding model of both 
the association and dissociation phases for at least five concentra-
tions simultaneously, using the BIAevaluation 3.2 software (GE 
Healthcare). Buffer blanks were subtracted from the data sets 
used for kinetic analysis (double referencing). Chi2 values were 
below 3.5 in all cases. For the two-state reaction (conformational 
change) model, the apparent dissociation constants were cal-
culated from the rate constants: KD = 1/[(ka1/kd1) (1 + ka2/kd2)]. 
For the Langmuir binding model, the apparent equilibrium 
dissociation constants (KD) were calculated from the ratio of the 
dissociation and association rate constants (kd/ka).
resUlTs anD DiscUssiOn
generation of a single-chain 
recombinant Form of gc1q
A strategy derived from that used for expression of a single 
polypeptide protein containing three consecutive copies of 
the globular domain of adiponectin was chosen to produce 
C1q-scGR (17). As revealed by the X-ray crystal structures of 
the globular domains of adiponectin (32) and of C1q (10), the 
N- and C-termini of the three gC1q modules emerge at the base 
of the trimer. Short 3-amino acid linkers can thus connect the 
adjacent monomers A–C and C–B. The 5′-3′ A–C–B order chosen 
to generate C1q-scGR also corresponds to that of the three C1q 
genes on chromosome 1p (33) (Figure 1A).
A first attempt to produce recombinant C1q-scGR was per-
formed using a baculovirus/insect cells expression system, but the 
production yield was rather low since only 1 mg purified protein 
was recovered per liter of cell culture supernatant. In addition, the 
recombinant material was heterogeneous, consisting of a mixture 
of glycosylated and unglycosylated species (data not shown). 
Recombinant C1q-scGR was next produced in stably transfected 
293-F mammalian cells and purified by cation-exchange chro-
matography. Up to 50  mg C1q-scGR could be purified from 
one liter of 293-F cells supernatant, which represents a 50-times 
higher yield compared to the baculovirus-infected insect cells. 
SDS-PAGE analysis showed a single band with an apparent mass 
of approximately 45  kDa under reducing and non-reducing 
conditions (Figure 1B).
N-terminal sequence analysis yielded the single sequence 
Lys–Asp–Gln–Pro–Arg, starting as expected at residue Lys 88 of 
C1qA chain. Mass spectrometry analysis yielded three peaks with 
masses of 47,749.84, 47,897.45, and 48,043.18 Da, accounting for 
a polypeptide chain with a predicted mass of 45,691.89 Da, and 
additional masses of 2059, 2205, and 2350 Da, corresponding to 
the three types of biantennary N-glycans (monosialylated, mono-
sialylated fucosylated, and bisialylated) identified previously in 
serum-derived C1q (34, 35). The single N-glysosylation site at 
Asn 124 of C1qA is thus glycosylated in recombinant C1q-scGR. 
Sialidase treatment resulted in the appearance of two peaks 
with masses of 47,615.55 and 47,453.09  Da, compatible with 
asialylated biantennary N-glycans, fucosylated, or not (expected 
masses 1914 and 1768 Da).
Analysis of C1q-scGR by sedimentation velocity at three 
protein concentrations (0.9, 2.5, and 5 mg/ml) yielded a major 
peak accounting for 95 ± 3% of the signal with a sedimentation 
coefficient of 2.14 ±  0.4  S. Analysis in non-interacting species 
yielded a molecular mass of 41.4 ± 2 kDa, which is close to the 
mass measured by mass spectrometry, indicating that C1q-scGR 
is a monomer (Figure 1C).
X-ray crystal structure of c1q-scgr
Although sialidase treatment of serum-derived C1q-GR had been 
required to obtain crystals of this protein suitable for structure 
determination (10), the presence of sialic acids in C1q-scGR was 
not an obstacle to the determination of its crystal structure. Its 
X-ray structure, refined at 1.35 Å resolution (Table 1), allowed 
us to check that the linkers did not introduce any distortion. 
The recombinant and serum-derived C1q globular domains are 
indeed almost identical, as shown by their very small 0.1 Å RMS 
deviation on the 331 Cα common positions (Figure  2A). The 
main-chain trace of the segment encompassing the C–B linker 
and the first two residues of gC1qB (GSAKA) were modeled into 
the electron density (Figure 2B). This more rigid C–B linker only 
slightly alters the main-chain position of the two preceding and 
FigUre 2 | crystal structure of c1q-scgr and its comparison with 
c1q-gr. (a) The global superposition of C1q-scGR (gray) and C1q-GR 
(cyan) structures illustrates their similarity, with only 0.1 Å RMS deviation on 
331 common Cα positions. The A–C labels corresponding to the three 
C1q-GR subunits are shown in blue. The calcium ion is shown as a golden 
sphere. The N-terminal and C-terminal ends are shown in green and 
magenta, respectively. More details of the C–B (red) and A–C (orange) linkers 
are provided in (B) and (c), respectively. The green and magenta arrows link 
the details in these zooming sections with the positions in the sequences 
shown below. (D) In the absence of calcium in the crystallization reservoir, the 
calcium-binding site is occupied by a magnesium ion, as illustrated here in 
the 2mFo–DFc map contoured at 2 σ level. Introducing a calcium ion in the 
model at this position deteriorates the Rfree factor by 2% and introduces a 
negative peak at this position in the Fo–Fc electron density map (not shown). 
(e) The ion substitution does not alter the structure of the calcium-binding 
site environment, as illustrated by the superposition of the structures of 
C1q-GR (cyan), C1q-scGR with calcium (magenta), and C1q-scGR with 
magnesium (gray).
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following residues, but the positions of their side-chains are con-
served (Figure 2B). The A–C linker is more flexible, and only the 
first two residues of gC1qC were modeled into the electron den-
sity (Figure 2C). All the water molecules except one correspond 
to those observed in the structure of the plasma-derived protein 
(PDB code 2wnv) (36). In the absence of calcium in the reservoir 
solution, the electron density filling the calcium-binding site 
is best modeled as a magnesium ion (Figure 2D). With a RMS 
deviation of 0.08 Å on the 340 Cα common positions, the two 
refined structures (Table  1) are almost identical except for the 
nature of the bound ion, which is either magnesium or calcium. 
Thus, this ion substitution does not alter the calcium-binding 
environment and is reversible (Figure 2E). The presence of a sin-
gle calcium (or magnesium) ion at the top of the heterotrimeric 
assembly has been proposed to contribute to the stability of the 
recognition domain of C1q (10).
The X-ray crystal structure of a single-chain version of the 
homotrimeric globular head of adiponectin had validated the 
strategy used to generate the recognition domain of this C1q-
related protein in a recombinant form (37). The fact that the 
3D structure of C1q-scGR is virtually identical to that of the 
three-chain C1q-derived fragment shows that this strategy can 
be extended to other proteins containing trimeric gC1q domains.
Functional Properties of c1q-scgr
The interaction properties of C1q-scGR were analyzed by 
surface plasmon resonance (SPR) and compared to those of 
serum-derived C1q-GR, using known physiological ligands 
of C1q: the receptor for the globular heads of C1q (gC1qR), 
CRT, the long pentraxin PTX3, and heparin. All ligands were 
immobilized on the surface of a sensor chip and the serum-
derived and recombinant forms of C1q-GR were used as 
soluble analytes. Both C1q-scGR and C1q-GR bound to the 
immobilized ligands with comparable association and dissocia-
tion rate constants, yielding comparable apparent KD values in 
the sub-micromolar range (Figure  3; Table  2). This indicated 
that the recombinant single-chain protein retained the binding 
capacities of its serum-derived counterpart and was therefore 
fully functional. The KD values obtained here for the interaction 
with CRT (494–510 nM) and gC1qR (304–344 nM) were in the 
same range as those reported previously for binding of C1q-GR 
to CRT (830 nM) (21) and gC1qR (370 nM) (38). The KD value 
obtained for binding to heparin (51 nM) is slightly lower than 
that obtained previously for the interaction of C1q-GR with 
6 kDa heparin (154 nM) (36), a difference that might be explained 
by the higher molecular weight heparin (15 kDa) used in the 
present study. Similar results were obtained when the binding 
experiments were performed in the absence of added calcium in 
the running buffer (not shown). In light of our structural data, 
it is likely that the calcium-binding site was still occupied under 
these conditions, since no chelating agent such as EDTA was 
used to remove the bound ion.
When the interaction experiments were performed using full-
length C1q as soluble analyte, the binding affinities for all ligands, 
except CRT, were in the nanomolar range (Figure 3; Table 2). The 
observation that the C1q globular domain binds to immobilized 
gC1qR, PTX3, and heparin with a lower affinity (41- to 47-, 24- to 
32-, and 32-fold, respectively) than intact C1q is consistent with 
the fact that C1q-scGR and C1q-GR lack the binding avidity of 
the hexameric C1q molecule. The decrease in affinity resulted 
mainly from a decrease in the ka value, the kd remaining essentially 
in the same range. A similar 44-fold decreased affinity has been 
FigUre 3 | Kinetic analysis of the interaction of c1q-scgr, c1q-gr, and c1q with immobilized crT, gc1qr, PTX3, and heparin. The C1q samples 
(60 μl) were injected at the indicated concentrations over immobilized CRT, gC1qR, PTX3 in 50 mM Tris–HCl, 150 mM NaCl, 2 mM CaCl2, 0.005% surfactant P20, 
pH 7.4, and over biotinylated heparin in 10 mM Hepes, 150 mM NaCl, 0.005% surfactant P20, pH 7.4. Fits are shown as red lines and were obtained by global 
fitting of the data using a 1:1 Langmuir binding model, except for the C1q–CRT interaction for which a two-state reaction (conformational change) model was used.
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observed previously for the prion protein, another C1q ligand 
known to be recognized through C1q globular domain (39).
Proper kinetic analysis of the CRT–C1q interaction required 
the use of a two-state reaction binding model, taking into account 
conformational changes leading to an increasingly more stable 
complex formed in two steps, as reported previously for C1q 
binding to placenta-derived and recombinant CRT (21). The two 
groups of kinetic constants and the resulting apparent affinity 
constant (KD), are listed in Table 2. As proposed previously (21), 
our data also suggest that CRT recognition by intact C1q implies 
conformational changes that do not take place in the isolated GR 
domains. Interestingly, the apparent KD values obtained here for 
the interaction of CRT with C1q or its globular domain were all in 
the sub-micromolar range, suggesting an interaction mechanism 
differing from those involving other C1q ligands, such as gC1qR, 
PTX3, or the prion protein. It should be mentioned that a 2.4- to 
7-fold increase in the C1q versus C1q-GR affinity to placenta-
derived and recombinant CRT was observed previously, which 
corresponds anyway to a much lower avidity component com-
pared to the other C1q ligands. Further investigation, including 
site-directed mutagenesis and/or structural analyses, will be 
needed to propose a relevant model for the CRT–C1q-GR 
interaction.
Of note, the same experimental SPR settings did not allow us 
to compare the binding affinity of C1q and its globular regions 
for IgG, a classical C1q ligand. Indeed, although full-length C1q 
readily bound to immobilized human IgG when injected at a con-
centration of 10 nM, only very weak binding of C1q-GR (either 
TaBle 2 | Kinetic and dissociation constants for binding of c1q-scgr, c1q-gr, and c1q to immobilized c1q ligands.
soluble c1q 
sample
constants immobilized c1q ligands
crT gc1qr PTX3 heparin
C1q-scGR ka (M−1 s−1) 2.80 ± 0.33 × 103 2.22 ± 0.17 × 103 1.32 ± 0.24 × 103 2.51 ± 0.02 × 104
kd (s−1) 1.36 ± 0.04 × 10−3 6.70 ± 0.31 × 10−4 5.52 ± 0.66 × 10−4 1.29 ± 0.06 × 10−3
KD (nM) 494 ± 47 304 ± 26 444 ± 125 51.5 ± 2.7
C1q-GR ka (M−1 s−1) 4.63 ± 0.73 × 103 4.40 ± 0.77 × 103 4.59 ± 1.2 × 103 2.09 ± 0.22 × 104
kd (s−1) 2.34 ± 0.43 × 10−3 1.49 ± 0.20 × 10−3 2.17 ± 0.43 × 10−3 1.06 ± 0.08 × 10−3
KD (nM) 510 ± 88 344 ± 78 599 ± 21 51.5 ± 9.0
C1q ka (M−1 s−1) 6.80 ± 1.20 × 104 3.87 ± 1.27 × 104 5.49 ± 0.65 × 106
aka1 (M−1 s−1) 7.82 ± 0.12 × 103
aka2 (s−1) 4.72 ± 0.90 × 10−3
kd (s−1) 4.57 ± 1.3 × 10−4 6.72 ± 0.15 × 10−4 8.81 ± 1.50 × 10−3
akd1 (s−1) 4.20 ± 0.51 × 10−2
akd2 (s−1) 4.82 ± 1.12 × 10−4
KD (nM) 590 ± 105 7.20 ± 2.65 18.2 ± 2.6 1.60 ± 0.08
Values are the means ± SD of at least two separate experiments.
aThe association (ka1, ka2) and dissociation (kd1, kd2) rate constants of the C1q–CRT interaction were determined by global fitting of the data using a two-state reaction binding model. 
The resulting dissociation constant was determined from the rate constants: KD = 1/[(ka1/kd1) (1 + ka2/kd2)].
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serum-derived or recombinant) injected at concentrations in the 
micromolar range was observed (Figure S1 in Supplementary 
Material). This precluded determination of kinetic constants 
for C1q-GR binding to IgG, but revealed, here too, a difference 
between full-length C1q and its recognition domains. It is well 
known that, under physiological conditions, efficient comple-
ment activation is triggered by multivalent binding of C1q to 
antigen–IgG complexes. These conditions can be reproduced 
artificially in ELISA tests using adsorbed heat-aggregated IgG. 
Therefore, it is not totally unexpected that the globular regions 
bind only weakly to immobilized single IgG molecules. The 
immobilized gC1qR and PTX3 molecules are naturally trimers 
and octamers, respectively, and it is expected that each of these 
ligands can bind to a single globular head of C1q, although with 
less affinity than to full-length C1q.
cOnclUsiOn
The availability of a recombinant functional form of the heterotri-
meric globular regions of C1q opens the way for deciphering the 
molecular basis of the binding versatility of C1q by mapping the 
residues involved in the recognition of its numerous targets using 
site-directed mutagenesis. Although it has been shown previously 
that the three isolated subunits mediate different individual bind-
ing properties (12), it is now possible to assess the effects of single 
residue mutations in the heterotrimeric context of C1q-scGR, as 
it occurs in native C1q. In addition, given the compact structure 
of the domain, it appears likely that recognition of certain ligands 
will involve residues contributed by several subunits (10), a 
hypothesis that can now be tested experimentally. The availability 
of two recombinant forms of C1q, the full-length protein (23) and 
its recognition domain, will allow comparison of their binding 
and effector properties, taking into account the avidity provided 
by the hexameric full-length C1q molecule.
In addition to basic research, such artificial gC1q molecules 
should be of interest for biomedical applications. The contribution 
of complement in the pathogenesis of many important diseases, 
including neurodegenerative, infectious, and autoimmune disor-
ders, is now well recognized and C1q is an attractive target for 
anti-complement therapy (40). C1q-scGR molecules, possibly 
engineered to form multimers, could thus be used in the fluid 
phase as natural competitors to inhibit the classical complement 
pathway at the initial recognition step without any risk of trigger-
ing the immune effector mechanisms mediated by the collagen-
like regions.
Engineered C1q-scGR molecules might also be used to 
functionalize magnetic nanobeads or hemoadsorption filters for 
in vitro blood cleansing, as described recently for the carbohy-
drate recognition domain of human MBL, a recognition protein 
of the lectin complement pathway (41, 42). MBL-coated devices 
were shown to efficiently capture bacteria, fungi, and endotoxins 
from whole human blood and are promising tools in sepsis 
therapy. Using C1q-scGR would broader the field of application 
of such devices beyond pathogenic microorganisms because of 
the capacity of C1q to recognize a variety of potentially noxious 
altered self elements such as amyloid fibrils and the toxic form of 
the prion protein. In addition, the fact that C1q specifically reacts 
with circulating immune complexes and acute-phase proteins 
such as pentraxins might open the way to the use of C1q-scGR 
hemoadsorption for the treatment of patients with severe autoim-
mune diseases such as SLE. It should be mentioned indeed that 
plasma immunoadsorption on a C1q-column (prepared with 
immobilized serum-purified porcine C1q) has been successfully 
used to treat a few SLE patients (43, 44). Using recombinant C1q-
scGR, it is now possible to address the potential contamination 
risks associated with animal serum-derived proteins.
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